Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance.
Bagchi A, Haidar JN, Eastman SW, Vieth M, Topper M, Iacolina MD, Walker JM, Forest A, Shen Y, Novosiadly RD, Ferguson KM. Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance. Molecular Cancer Therapeutics 2018, 17: molcanther.0575.2017. PMID: 29158469, PMCID: PMC5925748, DOI: 10.1158/1535-7163.mct-17-0575.Peer-Reviewed Original Research